Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.68 |
| ▸ | MLNR | O43193 | 1/20 | 0.68 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | DRD2 | P14416 | 1/20 | 0.68 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.68 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | MC4R | P32245 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447452 | 1.00 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| SCHEMBL29447446 | 1.00 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| SCHEMBL21731324 | 1.00 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| SCHEMBL21722773 | 1.00 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Hydrochloric Acid SCHEMBL23522271 | 0.99 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Hydrochloric Acid SCHEMBL23522270 | 0.99 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Hydrochloric Acid SCHEMBL30138857 | 0.99 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| SCHEMBL23761100 | 0.93 | SLC6A2 (0.59) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| SCHEMBL21731283 | 0.89 | CACNA2D1 (0.62) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| SCHEMBL21731162 | 0.89 | CACNA2D1 (0.62) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492195-B2 | Preparation method for and crystal form of 3-aryloxy-3-five-membered heteroaryl-propylamine compound | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2025-12-09 | — | — | US | disclosed |
| CN-115135644-B | Preparation method and crystal form of 3-aryloxy-3-five-membered heteroaryl-propylamine compound | 漳州片仔癀药业股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-114206859-B | 3-Aryloxy-3-five-membered heteroaryl-propylamine compound, and crystal forms and application thereof | 上海璃道医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112654616-B | 3-aryloxy-3-aryl-propylamines and application thereof | 漳州片仔癀药业股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023016249-A1 | METHOD FOR PREPARING 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYL-PROPYLAMINE COMPOUND | 上海璃道医药科技有限公司 | 2023-02-16 | — | — | WO | disclosed |
| CN-112566909-B | 3-aryloxy-3-five-membered heteroaryl-propylamine compound and application thereof | 上海璃道医药科技有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115135644-A | Preparation method and crystal form of 3-aryloxy-3-pentabasic heteroaryl-propylamine compound | 漳州片仔癀药业股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20220213075-A1 | 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND, AND CRYSTAL FORM AND USE THEREOF | SHANGHAI LEADO PHARMATECH CO. LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| US-20220119375-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3971181-A1 | 3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND, AND CRYSTAL FORM AND USE THEREOF | Shanghai Leado Pharmatech Co. Ltd. (CN) | 2022-03-23 | — | — | EP | disclosed |
| EP-3838900-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2021-06-23 | — | — | EP | disclosed |
| EP-3838899-A1 | 3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND AND USE THEREOF | Shanghai Leado Pharmatech Co. Ltd. (CN) | 2021-06-23 | — | — | EP | disclosed |
| EP-3838900-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2021-06-23 | — | — | EP | disclosed |
| EP-3838899-A1 | 3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND AND USE THEREOF | Shanghai Leado Pharmatech Co. Ltd. (CN) | 2021-06-23 | — | — | EP | disclosed |
| CN-112654616-A | 3-aryloxy-3-aryl-propylamine compounds and application thereof | 漳州片仔癀药业股份有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-112566909-A | 3-aryloxy-3-five-membered heteroaryl-propylamine compound and application thereof | 上海璃道医药科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2020228789-A1 | 3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND, AND CRYSTAL FORM AND USE THEREOF | 上海璃道医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| CN-111943943-A | 3-aryloxy-3-pentabasic heteroaryl-propylamine compound and crystal form and application thereof | 上海璃道医药科技有限公司 | 2020-11-17 | — | — | CN | disclosed |
| WO-2020035040-A1 | 3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND AND USE THEREOF | 上海璃道医药科技有限公司 | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035040-A1 | 3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND AND USE THEREOF | 上海璃道医药科技有限公司 | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213075-A1 | 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND, AND CRYSTAL FORM AND USE THEREOF | TRPM5, TRPV5, TRPM7 | SLC6A4 109/4885SLC6A2 353/4885SLC6A3 76/4885 |
| US-12492195-B2 | Preparation method for and crystal form of 3-aryloxy-3-five-membered heteroaryl-propylamine compound | TRPC7, TRPV1, TRPC5 | SLC6A4 110/4885SLC6A2 533/4885SLC6A3 165/4885 |
| US-20220119375-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | TRPV1, TRPA1, TRPC7 | SLC6A4 172/4885SLC6A2 335/4885SLC6A3 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.